Search Results

Rafa Laboratories, LTD., a leading manufacturer of Emergency Medical Solutions, and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, aim to enhance the national preparedness for nerve agent emergencies by developing a new design for Rafa’s pediatric atropine autoinjectors.

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.

Rafa Laboratories LTD. was awarded a follow-on production agreement for a total value of over $45 million from the Defense Department’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.

Rafa Laboratories LTD. (“Rafa”) and ExCEEd Orphan s.r.o (“ExCEEd”) announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe (“CEE”) and Israel.

Rafa Laboratories LTD. (" Rafa ") is pleased to announce the U.S. Food and Drug Administration has approved its “first in market” 10 mg midazolam autoinjector for the treatment of status epilepticus in adults.